This article is more than 5 years old. Information may no longer be current.

Spark Therapeutics reports $16.9 million net loss in third quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Spark Therapeutics reported a net loss of $16.9 million, or $0.70 per basic and diluted share, in the third quarter compared with a net loss of $6.8 million, or $1.22 per basic and diluted share, in the same quarter of 2014, according to a press release.

Revenue was reported at $1.3 million in the third quarter compared with no revenue reported in the same quarter of 2014. The increase was attributed to a collaboration with Pfizer.

Research and development expenses were reported at $11.8 million in the third quarter compared with $4.7 million in the same quarter of 2014. The increase was partially attributed to expenses related to clinical trials for SPK-RPE65.